Literature DB >> 2480079

Phosphorylation of 3'-azido-2',3'-dideoxyuridine and preferential inhibition of human and simian immunodeficiency virus reverse transcriptases by its 5'-triphosphate.

B F Eriksson1, C K Chu, R F Schinazi.   

Abstract

3'-Azido-2',3'-dideoxyuridine-5'-triphosphate was found to be a potent and highly selective inhibitor of human immunodeficiency virus type 1 and simian immunodeficiency virus reverse transcriptases. The affinity of 3'-azido-2',3'-dideoxyuridine-5'-triphosphate for the reverse transcriptases was similar to that observed for 3'-azido-3'-deoxythymidine-5'-triphosphate. Both compounds were competitive inhibitors with respect to the normal substrate dTTP and served at least 100 times better as substrates than did dTTP. In contrast, cellular DNA polymerase alpha showed an about 60-times-higher preference for dTTP as substrate than for either inhibitor. The phosphorylation of thymidine in human peripheral blood mononuclear cell extracts was inhibited in a competitive manner by both 3'-azido-2',3'-dideoxyuridine and 3'-azido-3'-deoxythymidine, with apparent inhibition constants of 290 and 3.4 microM, respectively. The Michaelis-Menten constant, Km, for thymidine was 7.0 microM. 3'-Azido-2',3'-dideoxyuridine and 3'-azido-3'-deoxythymidine both served as substrates, with apparent Km values of 67 and 1.4 microM, respectively. The maximal rates of phosphorylation with 3'-azido-2',3'-dideoxyuridine and 3'-azido-3'-deoxythymidine were 40 and 30%, respectively, of the rate with thymidine. The different affinities of 3'-azido-2',3'-dideoxyuridine and 3'-azido-3'-deoxythymidine for the thymidine kinase and the Km values observed with these compounds as substrates may explain the difference in effects on human immunodeficiency virus type 1 replication in infected peripheral blood mononuclear cells observed when equimolar concentrations of the two compounds are compared.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2480079      PMCID: PMC172746          DOI: 10.1128/AAC.33.10.1729

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

1.  Human deoxythymidine kinase. I. Purification and general properties of the cytoplasmic and mitochondrial isozymes derived from blast cells of acute myelocytic leukemia.

Authors:  L S Lee; Y C Cheng
Journal:  J Biol Chem       Date:  1976-05-10       Impact factor: 5.157

2.  Treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex with a regimen of 3'-azido-2',3'-dideoxythymidine (azidothymidine or zidovudine) and acyclovir. A pilot study.

Authors:  A Surbone; R Yarchoan; N McAtee; M R Blum; M Maha; J P Allain; R V Thomas; H Mitsuya; S N Lehrman; M Leuther
Journal:  Ann Intern Med       Date:  1988-04       Impact factor: 25.391

3.  Comparative activity of 2',3'-saturated and unsaturated pyrimidine and purine nucleosides against human immunodeficiency virus type 1 in peripheral blood mononuclear cells.

Authors:  C K Chu; R F Schinazi; B H Arnold; D L Cannon; B Doboszewski; V B Bhadti; Z P Gu
Journal:  Biochem Pharmacol       Date:  1988-10-01       Impact factor: 5.858

4.  DNA-dependent DNA polymerases from HeLa cell nuclei. II. Template and substrate utilization.

Authors:  A Schlabach; B Fridlender; A Bolden; A Weissbach
Journal:  Biochem Biophys Res Commun       Date:  1971-08-20       Impact factor: 3.575

5.  1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine. A highly potent and selective anti-HIV agent.

Authors:  M M Mansuri; J E Starrett; I Ghazzouli; M J Hitchcock; R Z Sterzycki; V Brankovan; T S Lin; E M August; W H Prusoff; J P Sommadossi
Journal:  J Med Chem       Date:  1989-02       Impact factor: 7.446

6.  Anti-retrovirus activity of 3'-fluoro- and 3'-azido-substituted pyrimidine 2',3'-dideoxynucleoside analogues.

Authors:  J Balzarini; M Baba; R Pauwels; P Herdewijn; E De Clerq
Journal:  Biochem Pharmacol       Date:  1988-07-15       Impact factor: 5.858

7.  An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction.

Authors:  H Masur; M A Michelis; J B Greene; I Onorato; R A Stouwe; R S Holzman; G Wormser; L Brettman; M Lange; H W Murray; S Cunningham-Rundles
Journal:  N Engl J Med       Date:  1981-12-10       Impact factor: 91.245

8.  Pyrophosphate analogues as inhibitors of herpes simplex virus type 1 DNA polymerase.

Authors:  B Eriksson; A Larsson; E Helgstrand; N G Johansson; B Oberg
Journal:  Biochim Biophys Acta       Date:  1980-03-28

9.  Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency.

Authors:  M S Gottlieb; R Schroff; H M Schanker; J D Weisman; P T Fan; R A Wolf; A Saxon
Journal:  N Engl J Med       Date:  1981-12-10       Impact factor: 91.245

10.  The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3'-azido-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly dependent on the cell species.

Authors:  J Balzarini; R Pauwels; M Baba; P Herdewijn; E de Clercq; S Broder; D G Johns
Journal:  Biochem Pharmacol       Date:  1988-03-01       Impact factor: 5.858

View more
  5 in total

1.  Activities of the four optical isomers of 2',3'-dideoxy-3'-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes.

Authors:  R F Schinazi; C K Chu; A Peck; A McMillan; R Mathis; D Cannon; L S Jeong; J W Beach; W B Choi; S Yeola
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

2.  Synthesis and evaluation of 2'-substituted cyclobutyl nucleosides and nucleotides as potential anti-HIV agents.

Authors:  Yongfeng Li; Shuli Mao; Michael W Hager; Kimberlynne D Becnel; Raymond F Schinazi; Dennis C Liotta
Journal:  Bioorg Med Chem Lett       Date:  2007-04-03       Impact factor: 2.823

3.  Development of an optimized dose for coformulation of zidovudine with drugs that select for the K65R mutation using a population pharmacokinetic and enzyme kinetic simulation model.

Authors:  Selwyn J Hurwitz; Ghazia Asif; Nancy M Kivel; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

4.  A rapid non-culture-based assay for clinical monitoring of phenotypic resistance of human immunodeficiency virus type 1 to lamivudine (3TC).

Authors:  J García Lerma; R F Schinazi; A S Juodawlkis; V Soriano; Y Lin; K Tatti; D Rimland; T M Folks; W Heneine
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

5.  Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.

Authors:  R F Schinazi; A McMillan; D Cannon; R Mathis; R M Lloyd; A Peck; J P Sommadossi; M St Clair; J Wilson; P A Furman
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.